To access this element change to forms mode OFF
Grant Award View - GA204257
Understanding and averting blood cancer resistance to therapy
GA ID:
GA204257
Agency:
National Health and Medical Research Council (NHMRC)
Approval Date:
10-Sep-2021
Publish Date:
6-Dec-2021
Category:
Medical Research
Grant Term:
1-Jan-2022 to 31-Dec-2026
Value (AUD):
$5,500,000.00
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
NHMRC 20/21 1.1 Health and Medical Research
Grant Program:
Synergy Grants
Grant Activity:
Understanding and averting blood cancer resistance to therapy
Purpose:
Blood cancers account for one-sixth of all cancer deaths. To substantially reduce this we need to establish why current treatments, including new targeted and immune therapies, fail. We are bringing together experts in different areas of science (biology, bioinformatics, imaging, immunology) and medicine (molecular diagnosis, treatment) to dissect why leukaemias and lymphomas become resistant to new therapies and design strategies to either prevent resistance occurring or to overcome it.
GO ID:
GO Title:
Synergy Grants 2021
Internal Reference ID:
2021/GNT2011139
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
Yes
Confidentiality Reason(s) - Contract:
Privacy Act 1988
Intellectual property
Intellectual property
Confidentiality - Outputs:
Yes
Confidentiality Reason(s) - Outputs:
Intellectual property
Grant Recipient Details
Recipient Name:
The Walter and Eliza Hall Institute of Medical Research
Recipient ABN:
12 004 251 423
Grant Recipient Location
Suburb:
Parkville
Town/City:
Parkville
Postcode:
3052
State/Territory:
VIC
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
VIC
Postcode:
Country:
AUSTRALIA